Control mid-market fund research profile
True North is an India-focused private-equity and private-credit manager that began as India Value Fund Advisors. Its PE strategy partners with entrepreneurs in consumer, financial services, healthcare and technology, while its credit business provides bespoke financing to middle-market companies.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
True North uses a control mid-market approach across Health, fin services, consumer.
Current evidence
True North’s March 2026 sustainability disclosures show Fund VII fundraising in progress as of March 31, 2025 with two investments made from capital raised, while its current partner-company page identifies a live private-equity portfolio including Accion Labs, Atria Convergence Technologies, Anthem Biosciences, Biocon Biologics, Cloudnine, HomeFirst, Nivara Home Finance, Niva Bupa, NSE, QuEST Global, SeedWorks and Vistaar Finance.
Strategy
Control mid-market
Sector focus
Health, fin services, consumer
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
True North’s March 2026 sustainability disclosures show Fund VII fundraising in progress as of March 31, 2025 with two investments made from capital raised, while its current partner-company page identifies a live private-equity portfolio including Accion Labs, Atria Convergence Technologies, Anthem Biosciences, Biocon Biologics, Cloudnine, HomeFirst, Nivara Home Finance, Niva Bupa, NSE, QuEST Global, SeedWorks and Vistaar Finance.
Investor questions
True North is covered in Rupeia's private equity research universe. The current public record describes the strategy as Control mid-market, with a sector focus of Health, fin services, consumer. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to True North in the reviewed public sources: Accion Labs, Atria Convergence Technologies, Anthem Biosciences, Biocon Biologics, Cloudnine, HomeFirst, Nivara Home Finance, Niva Bupa, NSE, QuEST Global, SeedWorks, Vistaar Finance. It does not represent a complete current portfolio unless the manager has published one.
True North’s 2024 ESG report publishes fund-level counts and exits: Fund I had seven investments and seven full exits; Fund IV had 14 full exits and two partial exits. The report does not provide a single consolidated India IRR or DPI. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: The ESG report discloses PE fund sizes from INR 1,170M for Fund I to INR 44,324M for Fund V and INR 39,902M for Fund VI; these are vehicle-level figures from the report.. Public terms or access information: Private-equity minority, significant-minority and majority investments; private-credit Fund I is reported at ₹2,700 Cr including co-investment and redeployment, with Fund II targeting ₹1,500 Cr.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Vishal Nevatia (CEO and Managing Partner); Divya Sehgal (Partner); Srikrishna Dwaram (Co-Managing Partner, Private Equity); Satish Chander (Co-Managing Partner, Private Equity). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund VII’s final size, remaining deployment and fund-level net returns are not publicly disclosed; private-credit activity is tracked separately in the directory..
2026-03-31: True North’s March 2026 sustainability disclosures show Fund VII fundraising in progress as of March 31, 2025 with two investments made from capital raised, while its current partner-company page identifies a live private-equity portfolio including Accion Labs, Atria Convergence Technologies, Anthem Biosciences, Biocon Biologics, Cloudnine, HomeFirst, Nivara Home Finance, Niva Bupa, NSE, QuEST Global, SeedWorks and Vistaar Finance.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.